The Role of Inflammation in Cholestatic Liver Injury
Jie Chen,Shujun Zhang
DOI: https://doi.org/10.2147/jir.s430730
IF: 4.5
2023-10-13
Journal of Inflammation Research
Abstract:Jie Chen, Shujun Zhang Chongqing Key Laboratory of Infectious Diseases and Parasitic Diseases, Department of Infectious Diseases, the First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China Correspondence: Shujun Zhang, Tel/Fax +86-23-89012427, Email Cholestasis is a common clinical event in which bile formation and excretion are blocked, leading to retention of bile acids or bile salts; whether it occurs intra- or extrahepatically, primary or secondary, its pathogenesis is still unclear and is influenced by a combination of factors. In a variety of inflammatory and immune cells such as neutrophils, macrophages (intrahepatic macrophages are also known as Kupffer cells), mast cells, NK cells, and even T cells in humoral immunity and B cells in cellular immunity, inflammation can be a "second strike" against cholestatic liver injury. These cells, stimulated by a variety of factors such as bile acids, inflammatory chemokines, and complement, can be activated and accumulate in the cholestatic liver, and with the involvement of inflammatory mediators and modulation by cytokines, can lead to destruction of hepatocytes and bile duct epithelial cells and exacerbate (and occasionally retard) the progression of cholestatic liver disease. In this paper, we summarized the new research advances proposed so far regarding the relationship between inflammation and cholestasis, aiming to provide reference for researchers and clinicians in the field of cholestatic liver injury research. Keywords: inflammation, immune cells, cholestasis, cholestatic liver injury Cholestasis is a pathological condition in which the formation, secretion, and excretion of bile flow are inhibited by various factors, resulting in the inability of bile to drain smoothly into the duodenum and thus return to the blood. 1 In the early stage, there is no specific clinical manifestation, only an increase in serum alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) levels; some patients may experience weakness, nausea, poor appetite, and epigastric discomfort. After gradual progression, jaundice, skin itching, fatigue, steatorrhea, yellow tumor, hepatic osteodystrophy, and fat-soluble vitamin deficiency may occur. In severe cases, it may even lead to liver failure and death. 2 Hepatobiliary disorders characterized by cholestasis are called cholestatic liver diseases, including primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), intrahepatic cholestasis in pregnancy syndrome (ICP), IgG4-related sclerosing cholangitis, and progressive familial intrahepatic cholestasis (PFIC). Cholestasis can also occur in alcoholic liver disease, viral hepatitis, drug-induced liver injury, and non-alcoholic fatty liver disease. 3 The occurrence of cholestasis is associated with abnormal bile duct cell proliferation, peribiliary fibrosis, myofibroblast activation, toxic bile acid accumulation, and bile duct reactions, all of which can drive disease progression. 4 The processes of cholestasis and cholestatic liver injury are extremely complex, and the etiology of cholestatic liver injury varies greatly. The invasion of inflammatory cells, which facilitates bile duct cell death, results in blockage of bile ducts and abnormal bile acid excretion in PBC and PSC, etc. And the accumulating bile acids might act as a second hit, causing inflammation and fibrosis. 5 In In cholestatic liver diseases such as ICP and PFIC, which are due to abnormalities of the bile salt transporter pump, the first strike is bile acid accumulation due to inadequate bile acid excretion, which causes a second hit of immunological imbalance, inflammation, and fibrosis, leading to aggravation of cholestatic liver injury. 6,7 Inflammation might be the initial cause of cholestasis and the following hit to the liver. As a result, many scientists regard regulation of the inflammatory response as a viable therapeutic target for cholestasis and its accompanying liver harm. 8 Therefore, this article provides a review of the mechanisms of inflammation and cholestasis from the aspects of inflammatory cells, humoral immunity, inflammatory factors, and Inflammatory vesicles, etc. Neutrophils are usually the first responders to the inflammatory response. During bacterial infections, neutrophils are able to transform from a resting state to an activated state stimulated by C5a, lipopolysaccharides (LPS), and cytokines, and thus have a direct role in clearing pathogens. 9 Usually, neutrophils execute their cytotoxicity through the production of reactive oxygen species (ROS) and hypochlorous acid, both of which have strong toxic effects on liver cells. 10 In addition, neutrophils can produce a substance called serine protease, which not only has a dire -Abstract Truncated-
immunology